The Global Antibody Drug Conjugates Market is estimated to be valued at US$ 5.38 billion in 2023 and is expected to exhibit a CAGR of 14.2% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Antibody drug conjugates are biopharmaceutical drugs consisting of monoclonal antibodies conjugated to cytotoxic agents payload via biological or chemical linker. They combine the targeting capabilities of antibodies and the cancer-killing ability of chemotherapy together. This allows selective delivery of chemotherapy specifically to tumor cells with minimal off-target toxicities.
Market key trends:
One of the key trends in the antibody drug conjugates market is the continuous research and development of new antibody drug conjugates and novel linker and payload combinations with higher efficacy and lower toxicity. For instance, Daiichi Sankyo’s Enhertu, an HER2-targeted antibody drug conjugate has shown promising results against breast and gastric cancers in clinical trials. Its approval and commercial success have demonstrated the potential of antibody drug conjugates for targeted cancer therapy.
The global antibody drug conjugates market is segmented into type, technology, target, indication, end user and geography. By type, the market is classified into cleavable linker ADC and non-cleavable linker ADC. The non-cleavable linker ADC segment dominates the market owing to its ability to provide a steady release of cytotoxic agents inside tumor cells leading to longer duration of action.
The Global Antibody Drug Conjugates Market is expected to witness high growth, exhibiting CAGR of 14.2% over the forecast period, due to increasing prevalence of cancer.
The US region dominated the market in 2023, accounting for over 30% revenue share owing to presence of major players and faster adoption of advanced therapeutics. Europe and Asia Pacific are expected to witness high growth during the forecast period due to increasing R&D investments and development activities in antibody drug conjugate therapeutics.
Key players operating in the antibody drug conjugates market are AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd. Major players are focused on partnerships, collaborations and developing innovative antibody drug conjugates.